Gilead Sciences: Summary

Gilead Sciences

Biopharmaceutical, healthcare, therapeutics, infectious diseases, oncology

Gilead Sciences aims to deliver transformative therapies that improve health outcomes and advance health equity for all people.

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures, and commercializes therapies for critical diseases. The company is a leader in HIV treatment and is expanding its pipeline to address various therapeutic areas including oncology and inflammation.

Diverse pipeline across Virology, Oncology, and Inflammation; Commitment to health equity and community impact; World-class research and development capabilities; Extensive portfolio of over 25 medicines offered globally

Gilead's therapies are most valuable in treating HIV, various cancers, and rare liver diseases, as well as in advancing health equity initiatives.

Leading funder of HIV programs in the U.S.; Strong focus on health equity and community engagement; Robust pipeline with potential best-in-class therapies

Gilead's strengths include its innovative research capabilities, a strong commitment to addressing critical health issues, and a diverse range of therapeutic offerings.

Gilead positions itself as a leader in biopharmaceutical innovation, particularly in the areas of HIV, oncology, and inflammation.

The target users include healthcare providers, patients with critical diseases, and communities in need of health equity initiatives.

Learn More About Gilead

• biopharmaceutical

• HIV treatment

• health equity

• oncology

Leading with Innovation

Innovative, compassionate, authoritative

Gilead is distinguished by its long-standing leadership in HIV treatment and its commitment to developing long-acting medications for both prevention and treatment.

Gilead's brand identity is centered around scientific innovation and a commitment to improving global health outcomes.

1987-06-22

• Michael L. Riordan